SEC
PTCT icon

Seven Eight Capital’s PTC Therapeutics PTCT Stock Holding History

Seven Eight Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,415
Closed -$563K – 909
2024
Q2 		$563K Sell
18,415
-40,277
-69% -$1.3M 0.06% 494
2024
Q1 		$1.71M Buy
58,692
+35,055
+148% +$982K 0.18% 170
2023
Q4 		$651K Sell
23,637
-41,085
-63% -$939K 0.08% 373
2023
Q3 		$1.45M Buy
+64,722
New +$2.41M 0.17% 159
2022
Q4 		– Sell
-4,945
Closed -$248K – 586
2022
Q3 		$248K Buy
+4,945
New +$242K 0.05% 417
2020
Q1 		– Sell
-33,300
Closed -$1.6M – 651
2019
Q4 		$1.6M Buy
+33,300
New +$1.42M 0.08% 356
2018
Q4 		– Sell
-66,889
Closed -$3.14M – 677
2018
Q3 		$3.14M Buy
+66,889
New +$2.77M 0.19% 165
2018
Q2 		– Sell
-8,000
Closed -$216K – 558
2018
Q1 		$216K Buy
+8,000
New +$203K 0.02% 331
2015
Q3 		– Sell
-1,100
Closed -$53K – 654
2015
Q2 		$53K Sell
1,100
-900
-45% -$52.5K 0.06% 323
2015
Q1 		$122K Buy
+2,000
New +$122K 0.2% 173

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seven Eight Capital's PTCT Position: Q3 2024 in Review

Seven Eight Capital sold out of PTC Therapeutics (PTCT) in Q3 2024, closing a stake of 18,415 shares — an estimated $563K sold.

Seven Eight Capital first reported a position in PTCT in Q1 2015 and held it in 10 quarters. The position peaked at $3.14M in Q3 2018. 202 funds tracked by Wall St. Rank hold PTCT as of Q3 2024.

  • Seven Eight Capital reported no remaining PTC Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Seven Eight Capital sold 18,415 PTC Therapeutics shares in Q3 2024, an estimated $563K.
  • Seven Eight Capital first reported a position in PTC Therapeutics in Q1 2015 and held it in 10 quarters.
  • Seven Eight Capital's PTC Therapeutics position peaked at $3.14M in Q3 2018.
  • 202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2024.

Based on Seven Eight Capital's 13F filing for Q3 2024, filed 12 Nov 2024.